The antiplatelet function of prasugrel and clopidogrel

Not Applicable

• Conditions: Stable coronary artery disease

• Registration Number: JPRN-jRCT1031220254
• Lead Sponsor: Isoda Kikuo

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2022-08-08
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

1) Age is 20 years or older at the time of consent acquisition
2) Those who are judged by the doctor in charge to be DAPT indicated due to PCI schedule for stable coronary artery disease
3) Maintenance of aspirin (100 mg / day) as part of standard treatment
4) Those who have received sufficient explanation before participating in this research, and who have obtained sufficient understanding and voluntary written consent of the research subject

Exclusion Criteria

1) Platelet count<50000000000/L
2) Dialysis patients
3) Baseline ALT> 2.5 times the normal upper limit.
4) Pregnant or lactating women
5) Contraindications for prasugrel, clopidogrel, or stent placement
6) In addition, those who are judged by the principal investigator to be inappropriate as research subjects

Study & Design

• Study Type: Observational
• Study Design: Not specified